So is the CDx thinking that Jannsen will eventually run a trial to see if they use PromarkerD to determine dosing for patients newly initiating canaglifozin? Otherwise I don’t really see the value of the study other than it shows that canaglifozin works. What is the actual clinical utility here?
So is the CDx thinking that Jannsen will eventually run a trial...
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
85.5¢ |
Change
-0.005(0.58%) |
Mkt cap ! $111.9M | |||
| Open | High | Low | Value | Volume |
| 86.5¢ | 86.5¢ | 85.5¢ | $52.28K | 60.78K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 23891 | 85.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 89.0¢ | 19840 | 2 |
View Market Depth
| Last trade - 15.58pm 04/07/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |